The vascular disrupting agent
5,6-dimethylxanthenone-4-acetic acid (
DMXAA), a murine agonist of the stimulator of
interferon genes (
STING), appears to target the
tumor vasculature primarily as a result of stimulating pro-inflammatory
cytokine production from tumor-associated macrophages (TAMs). Since there were relatively few reports of
DMXAA effects in genetically-engineered mutant mice (GEMM), and models of
non-small cell lung cancer (NSCLC) in particular, we examined both the effectiveness and macrophage dependence of
DMXAA in various NSCLC models. The
DMXAA responses of primary
adenocarcinomas in K-rasLA1/+ transgenic mice, as well as syngeneic subcutaneous and metastatic
tumors, generated by a p53R172HΔg/+; K-rasLA1/+ NSCLC line (344SQ-ELuc), were assessed both by in vivo bioluminescence imaging as well as by histopathology. Macrophage-dependence of
DMXAA effects was explored by
clodronate liposome-mediated TAM depletion. Furthermore, a comparison of the vascular structure between subcutaneous
tumors and
metastases was carried out using micro-computed tomography (micro-CT). Interestingly, in contrast to the characteristic hemorrhagic
necrosis produced by
DMXAA in 344SQ-ELuc subcutaneous
tumors, this agent failed to cause hemorrhagic
necrosis of either 344SQ-ELuc-derived
metastases or autochthonous K-rasLA1/+ NSCLCs. In addition, we found that
clodronate liposome-mediated depletion of TAMs in 344SQ-ELuc subcutaneous
tumors led to non-hemorrhagic
necrosis due to
tumor feeding-vessel occlusion. Since NSCLC were comprised exclusively of TAMs with anti-inflammatory M2-like phenotype, the ability of
DMXAA to re-educate M2-polarized macrophages was examined. Using various macrophage phenotypic markers, we found that the
STING agonists,
DMXAA and the non-canonical endogenous cyclic dinucleotide, 2'3'-cGAMP, were both capable of re-educating M2 cells towards an M1 phenotype. Our findings demonstrate that the choice of preclinical model and the anatomical site of a
tumor can determine the vascular disrupting effectiveness of
DMXAA, and they also support the idea of
STING agonists having therapeutic utility as TAM repolarizing agents.